Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of the COVID-19 pandemic on Vogt-Koyanagi-Harada disease.
Muto T, Sakamoto M, Kusuda S, Haruyama Y, Machida S, Imaizumi S, Sekiryu T. Muto T, et al. Among authors: sekiryu t. Sci Rep. 2024 Jun 8;14(1):13211. doi: 10.1038/s41598-024-63957-1. Sci Rep. 2024. PMID: 38851824 Free PMC article.
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan.
Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T. Mukai R, et al. Among authors: sekiryu t. Sci Rep. 2024 May 22;14(1):11681. doi: 10.1038/s41598-024-62559-1. Sci Rep. 2024. PMID: 38778065 Free PMC article.
Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next.
Stahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Leal S, Schlief S, Schmelter T, Miller T, Köfüncü E, Fielder A; FIREFLEYE next Study Group. Stahl A, et al. JAMA Netw Open. 2024 Apr 1;7(4):e248383. doi: 10.1001/jamanetworkopen.2024.8383. JAMA Netw Open. 2024. PMID: 38687481 Free PMC article. Clinical Trial.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. Ophthalmology. 2024. PMID: 38382813 Free article. Clinical Trial.
117 results